PSMA与GRPR靶向PET在50例生化复发前列腺癌中的比较
该研究纳入50例生化复发前列腺癌患者,均行68Ga-RM2 PET/MRI及68Ga-PSMA11(23例)或18F-DCFPyL(27例)PET/CT,两次检查间隔1至60天(均值±标准差15.8±17.7天)。68Ga-RM2 PET阳性35例、阴性15例,68Ga-PSMA11/18F-DCFPyL PET阳性37例、阴性13例。
要点
- 68Ga-RM2与PSMA靶向PET在生化复发前列腺癌中均有检出价值。
- PSMA靶向显像额外检出36个病灶(13例),68Ga-RM2额外检出7个(4例)。
- 两种显像剂可能互补,有待更大样本验证个体化应用。
核心结论
- 在生化复发前列腺癌评估中,68Ga-RM2即使与更常用的68Ga-PSMA11/18F-DCFPyL相比仍是有价值的放射性药物。
- 需更大规模研究验证两类放射性药物的互补性是否最终可实现个体化医疗。
研究设计与样本
- 50例生化复发前列腺癌患者均接受68Ga-RM2 PET/MRI及68Ga-PSMA11(n=23)或18F-DCFPyL(n=27)PET/CT。
- 两次检查间隔1至60天(均值±标准差15.8±17.7天),收集所有病灶的SUVmax。
主要发现
- 68Ga-RM2 PET在50例中阳性35例、阴性15例;68Ga-PSMA11/18F-DCFPyL PET阳性37例、阴性13例。
- 两种扫描在32例患者中共同检出70个病灶。
关键数值与推荐
- 68Ga-RM2 PET阳性35例、阴性15例(共50例)。
- 68Ga-PSMA11/18F-DCFPyL PET阳性37例、阴性13例(共50例)。
临床怎么用
- 对生化复发前列腺癌患者,68Ga-RM2 PET/MRI与PSMA靶向PET/CT均可提供病灶检出信息。
- 当一种靶向PET结果不明确或阴性时,可考虑另一类放射性药物显像以发现互补病灶。
局限性
- 原文未报告
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Novel radiopharmaceuticals for PET are being evaluated for the diagnosis of biochemical recurrence (BCR) of prostate cancer (PC). We compared the gastrin-releasing peptide receptor-targeting 68Ga-RM2 with the prostate-specific membrane antigen (PSMA)-targeting 68Ga-PSMA11 and 18F-DCFPyL. Methods: Fifty patients underwent both 68Ga-RM2 PET/MRI and 68Ga-PSMA11 (n = 23) or 18F-DCFPyL (n = 27) PET/CT at an interval ranging from 1 to 60 d (mean ± SD, 15.8 ± 17.7 d). SUVmax was collected for all lesions. Results:68Ga-RM2 PET was positive in 35 and negative in 15 of the 50 patients. 68Ga-PSMA11/18F-DCFPyL PET was positive in 37 and negative in 13 of the 50 patients. Both scans detected 70 lesions in 32 patients. Forty-three lesions in 18 patients were identified on only 1 scan: 68Ga-RM2 detected 7 more lesions in 4 patients, whereas 68Ga-PSMA11/18F-DCFPyL detected 36 more lesions in 13 patients. Conclusion:68Ga-RM2 remains a valuable radiopharmaceutical even when compared with the more widely used 68Ga-PSMA11/18F-DCFPyL in the evaluation of BCR of PC. Larger studies are needed to verify that identifying patients for whom these 2 classes of radiopharmaceuticals are complementary may ultimately allow for personalized medicine.
引用
- Baratto L, Song H, Duan H, et al. PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2021. PMID: 33674398. doi:10.2967/jnumed.120.259630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。